MSCI ACWI IMI Immuno-Oncology Index

The MSCI ACWI IMI Immuno-oncology Index aims to represent the performance of a set of companies that are associated with research, development, and commercialization of products for cancer immunotherapy, also known as Immuno-oncology. Immuno-oncology is a form of cancer treatment that uses the power of the body’s own immune system to prevent, control and eliminate cancer.
Get in touch
Document downloads
Index code
752570
Inception date
March 28, 2023
Div Yld (%)
2.11
P/E
64.83
P/E Fwd
39.14
P/BV
4.58
Number of constituents
45
Index Market Cap
$2.49 T
Largest constituent Market Cap
$144.50 B
Smallest constituent Market Cap
$2.53 B
Average constituent Market Cap
$55.54 B
Median constituent Market Cap
$24.38 B
Data as of Sept. 30, 2024 

ESG metrics

Summary

MSCI ACWI IMI Immuno-Oncology Index

Implied Temperature Rise
<= 1.5°C
88.89% coverage

MSCI ACWI IMI

Implied Temperature Rise
> 2.0°C - < 3.2°C
94.69% coverage
MSCI ACWI IMI Immuno-Oncology Index
Score
Coverage
ESG Score
6.18
100.00%
UN Global Compact Violations % (*)
0.00%
100.00%
Red Flag ESG Controversies % (*)
0.00%
100.00%
MSCI ACWI IMI
Score
Coverage
ESG Score
6.72
88.49%
UN Global Compact Violations % (*)
0.15%
97.03%
Red Flag ESG Controversies % (*)
0.16%
97.03%

(*) Additional ESG factor not mentioned in the regulation but provided for transparency purposes.

Data available as of Sept. 30, 2024. The information was updated as part of the regular monthly update cycle.

MSCI ESG and climate ratings, research and data are produced by MSCI ESG Research LLC, a subsidiary of MSCI Inc. MSCI ESG Indexes, Analytics, Real Assets, and Private Capital Solutions are products of MSCI Inc. that utilize information from MSCI ESG Research LLC. MSCI Indexes are administered by MSCI Limited and MSCI Deutschland GmbH.

Want to learn more about MSCI indexes?
Get in touch.

Contact us